Overview Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole Status: Terminated Trial end date: 2019-05-07 Target enrollment: Participant gender: Summary An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors Phase: Phase 1 Details Lead Sponsor: ArQuleArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)Treatments: Albumin-Bound PaclitaxelAnastrozoleCarboplatinPaclitaxel